Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 121 to 135 of 163 results for copd

  1. Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)

    Evidence-based recommendations on amantadine (Lysovir), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza in children and adults.

    Technology appraisal guidance
    Published
    25 February 2009
    View recommendations

    Sections for TA168

  2. Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry (MIB113)

    NICE has developed a medtech innovation briefing (MIB) on the Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry .

    Medtech innovation briefing
    Published
    24 July 2017

  3. Community pharmacies: promoting health and wellbeing (NG102)

    This guideline covers how community pharmacies can help maintain and improve people’s physical and mental health and wellbeing, including people with a long-term condition. It aims to encourage more people to use community pharmacies by integrating them within existing health and care pathways and ensuring they offer standard services and a consistent approach. It requires a collaborative approach from individual pharmacies and their representatives, local authorities and other commissioners.

    NICE guideline
    Published
    2 August 2018
    View recommendations

    Sections for NG102

  4. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary care (CG12)

    This guideline has been updated and replaced by NICE guideline CG101.

    Clinical guideline
    Published
    25 February 2004

  5. AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images (DG55)

    Evidence-based recommendations on AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images

    Diagnostics guidance
    Published
    5 July 2023
    View recommendations

    Sections for DG55

  6. Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)

    Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making

    Evidence summary
    Published
    29 January 2013

  7. Chronic obstructive pulmonary disease: olodaterol (ESNM54)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    3 February 2015

  8. Chronic obstructive pulmonary disease: aclidinium/formoterol (ESNM57)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    28 April 2015

  9. Chronic obstructive pulmonary disease: beclometasone/formoterol (Fostair) (ESNM47)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    16 September 2014

  10. Chronic obstructive pulmonary disease: aclidinium bromide (ESNM8)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    7 January 2013

  11. Chronic obstructive pulmonary disease: glycopyrronium bromide (ESNM9)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    7 January 2013

  12. Chronic obstructive pulmonary disease: tiotropium/olodaterol (Spiolto Respimat) (ESNM72)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    10 May 2016

  13. Chronic obstructive pulmonary disease: indacaterol/glycopyrronium (Ultibro Breezhaler) (ESNM33)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    11 February 2014

  14. myCOPD for self-management of chronic obstructive pulmonary disease (MIB214)

    This advice has been updated and replaced by NICE medical technologies guidance 68.

    Medtech innovation briefing
    Published
    1 April 2020

  15. Roflumilast for the management of severe chronic obstructive pulmonary disease (TA244)

    This guidance has been updated and replaced by NICE technology appraisal guidance 461.

    Technology appraisal guidance
    Published
    25 January 2012